Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival.
Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland).
One of the hard-to-treat cancers that Ariad is targeting is a type of non-small cell lung cancer (NSCLC), which is characterized by abnormal expression of the proto-oncogene ALK.
This gene codes a protein (anaplastic lymphoma kinase) which is not normally expressed in healthy adult tissues – making it a promising target in Cancer.
Brigatinib is a small-molecule drug taking advantage of this target, and the strategy was recognized as a Breakthrough Therapy by the FDA. Though applicable to a range of cancers with ALK activity (ALK+), the most advanced clinical trials are in NSCLC.
Now, Ariad is presenting its updated results for brigatinib’s phase I/II trial which ran across the US and in 1 centre in Spain.